-
Health todayDementia new
Physical frailty and faster clinical decline on lecanemab in early Alzheimer's disease
In 187 patients starting lecanemab, physical frailty was linked to faster decline on the CDR-SB and more infusion-related reactions.
Peer-reviewed -
Data, models and systemsValue in health confirms
Lecanemab and donanemab for early Alzheimer's disease are not cost-effective in China
A lifetime Markov model found that neither lecanemab nor donanemab was cost-effective at current Chinese prices, from either perspective.
Peer-reviewed -
Health todayDementia refines
Cognition in healthy adults: modifiable risk factors linked to performance, not decline
Five modifiable dementia risk factors were linked to cognitive level, not decline, in 1,396 healthy adults aged 36 to 108.
Preprint · not peer-reviewed -
Health todayDementia refines
Eating difficulty marks functional vulnerability rather than triggering cognitive decline
In four ageing cohorts, new eating difficulty was associated with higher dementia-indicator risk, but tooth loss showed little adjusted association.
Peer-reviewed -
Data, models and systemsForecasts and their record new
Alzheimer's disease model links slower cognitive decline to later institutionalisation
In a memory clinic microsimulation, 30% slower MMSE decline delayed institutional care by 1.1 years, with similar time spent there.
Peer-reviewed -
Health todayDementia refines
Education and dementia: a schooling reform cut incidence and weakened genetic risk
A compulsory schooling reform showed that extra education lowered dementia incidence and weakened the link between genetic risk and dementia.
Peer-reviewed -
Health todayDementia new
Amyloid and tau stage in 2711 Sao Paulo autopsies, by age and cognitive status
In 2711 Sao Paulo autopsies, 19.6% had both amyloid and tau at biomarker-detectable levels, rising steeply with age.
Preprint · not peer-reviewed -
Health todayDementia refines
Lecanemab in real-world practice: pooled ARIA, discontinuation and cognitive outcomes
Any ARIA occurred in 15.1% of lecanemab-treated patients in real-world cohorts, rising to 34.1% in APOE e4 homozygotes.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 confirms
GLP-1 receptor agonists do not improve cognition or function in Alzheimer's disease or MCI
GLP-1 receptor agonists improved neither cognition nor disease progression in pooled trials, with more adverse events and discontinuation.
Peer-reviewed -
Tomorrow's worldInnovation in treatment new
VES001, an oral sortilin inhibitor, raised plasma and CSF progranulin in healthy adults
In a randomised placebo-controlled first-in-human trial, twice-daily oral VES001 for 7 days raised plasma progranulin by up to 49% and CSF progranulin by 18% from baseline.
Peer-reviewed -
Health todayDementia refines
Dementia incidence 9.7 per 1000 person-years, higher in low- and middle-income countries
Age- and sex-standardised all-cause dementia incidence was 9.7 per 1000 person-years across 22 cohorts in 18 countries.
Peer-reviewed -
Tomorrow's worldA changing climate new
More days above the WHO daily NO2 guideline are followed by faster cognitive decline
Among 12,235 English adults aged 50 and over, more days above the WHO daily NO2 guideline were followed by faster decline in memory and fluency, independent of annual mean exposure.
Preprint · not peer-reviewed